BioWorld

Feb. 6, 2002

SangStat Prices $77.6M Offering To Pay Off Loan, Stoke Reserves

Theratechnologies Partners Peptide In Japan With Sakai

InterMune’s Actimmune Enters Phase III For Ovarian Cancer

Aphton Raising $17.1M To Finance Clinical Programs

Other News To Note

Bush Budget Includes Increases In New Drug Application Fees

WASHINGTON Based on President George Bush’s proposed budget for fiscal year 2003, it appears that biotechnology companies filing drug applications with the FDA will be paying a higher cost. (BioWorld Today) Read More

Today's news in brief

BioWorld

BioWorld briefs for Jan 26, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 27, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Muted and missing M&As: JPM deals absent in 2026

BioWorld

For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...